<DOC>
	<DOC>NCT02946541</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin after oral administration in patients with type 2 diabetes who have inadequate glycemic control on diet and exercise.</brief_summary>
	<brief_title>A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin</brief_title>
	<detailed_description>1. Evogliptin 5mg Group: Administration with Evogliptin 5mg for 0-52 weeks. 2. Placebo Group: Administration with Placebo for 0-24 weeks, and with Evogliptin 5mg for 24-52 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Subjects with 6.5%≤HbA1c≤10.0% at screening Subjects untreated with oral hypoglycemic agents within 6 weeks prior to screening Subjects with 6.5%≤HbA1c≤10.0% at Visit 2 Subjects with 20kg/m2≤BMI≤40kg/m2 at screening Subjects with fasting plasma glucose≥270mg/dL at screening Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus Subjects with history of myocardial infarction, cerebral infarction within 6 months prior to screening Subjects with ALT and AST 2.5 times or higher than upper normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DA-1229</keyword>
	<keyword>evogliptin</keyword>
	<keyword>DPP-IV inhibitor</keyword>
	<keyword>Suganon</keyword>
	<keyword>DPP-4 inhibitor</keyword>
</DOC>